Nordic Nanovector raises NOK 225 million in private placements, begins phase II clinical trials in 74 sites in 23 countries and prepares to commercialize the company. These were some of the good news presented in the first quarter 2019 report.
Oslo Cancer Cluster’s member company Nordic Nanovector develops precision medicine against haematological cancers. These are the types of cancers affecting blood, bone marrow and lymph nodes – also known as leukaemia, lymphoma and myeloma. These cancers are notoriously difficult to treat and therefore have a highly unmet medical need.
On the morning of 23 May 2019, the CEO of Nordic Nanovector, Eduardo Bravo, presented some of the successes the company has had during the first quarter of 2019.
“As we advance the clinical development programmes with Betalutin, including PARADIGME, we are also beginning to initiate some of the other pre-commercialisation activities, such as manufacturing, that are crucial to ensure that we can submit our regulatory filing in a timely and efficient manner.”
The company’s highlights from the first quarter included raising approximately NOK 225 million in private placements.
They have also extended their clinical trials, known as the PARADIGME study, which address advanced, recurring follicular lymphoma. They now have phase II clinical trials in over 74 sites in 23 countries.
During the first quarter, Nordic Nanovector has also welcomed a new chairman to the Board of Directors – Jan H. Egberts, M.D. He is also the chairperson of the Board of Directors of Oslo Cancer Cluster member Photocure.
Lastly, Dr Mark Wright has been appointed Head of Manufacturing to lead the production of Nordic Nanovector’s therapies. This prepares Nordic Nanovector for future commercialisation and will hopefully lead to more precise treatments successfully reaching cancer patients.
- Visit Nordic Nanovector’s official website to view the webcast, read the press release and find out more about the company.